Form 4: Daxor Director Granted Stock Options Contingent on SEC Plan Approval

Daxor Corp. Director Joy S. Goudie was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Summary

• Joy S. Goudie, a Director of Daxor Corp. (DXR), was granted 2,500 stock options on June 24, 2025.
• The exercise price for these stock options is $9.29 per share.
• The grant of these options is contingent upon the approval by the U.S. Securities and Exchange Commission (SEC) of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• The options will vest in three installments: 833 options on June 24, 2025, 883 options on June 24, 2026, and 834 options on June 24, 2027.
• The stock options have an expiration date of June 24, 2030.
• Following this reported transaction, Joy S. Goudie beneficially owns 2,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management and shareholder interests, though the contingency on SEC approval introduces a minor element of uncertainty.

Positives

• The grant of stock options to a director helps align their interests with those of the shareholders, incentivizing long-term company performance.
• The options have a clear vesting schedule, promoting continued engagement and performance from the director over several years.

Negatives

• The grant of stock options is contingent on SEC approval of an amendment to the 2020 Incentive Compensation Plan, introducing a degree of uncertainty regarding the finalization of the grant.

Risks

• The primary risk is that the SEC may not approve the amendment to the Daxor Corporation 2020 Incentive Compensation Plan, which would prevent the stock options from becoming effective.

Future Outlook

The grant of stock options is a forward-looking incentive, contingent on future SEC approval of the amended 2020 Incentive Compensation Plan, and designed to align the director's long-term interests with the company's performance through a multi-year vesting schedule.

Industry Context

The granting of stock options to directors is a common practice in publicly traded companies across various industries. It serves as a key component of executive and director compensation, aiming to align the interests of leadership with those of shareholders by providing an equity stake in the company's future success.

Comparison to Industry Standards

• The practice of granting stock options to directors is a standard compensation mechanism widely adopted by public companies, comparable to practices seen in other small-cap biotechnology or medical device companies.
• The vesting schedule over multiple years is also a common approach to encourage long-term commitment and performance, similar to incentive plans at companies like Bio-Rad Laboratories or QuidelOrtho, which also utilize equity-based compensation for their leadership.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their financial interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: No direct impact on general employees is mentioned in this filing.
• Management: The director receives additional incentive compensation, potentially increasing their commitment and motivation.

Next Steps

• Approval by the U.S. Securities and Exchange Commission of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Subsequent vesting of the stock options on June 24, 2026, and June 24, 2027.

Key Dates

Keywords

Daxor Corp, DXR, SEC Form 4, Stock Options, Incentive Compensation Plan, Director Compensation, Beneficial Ownership, Equity Grant